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Dear Sir, The clinical use of oral anticoagulant therapy is challenging: while an insufficient dose may increase the risk of thromboembolism, an overdose is associated with an increased risk of serious bleeding (1, 2) . There is growing evidence suggesting the influence of polymorphisms in the genes encoding the cytochrome P-450 2C9 enzyme (CYP2C9) and the vitamin K epoxide reductase enzyme (VKORC1) on effective coumarin dose (2, 3) .
Acenocoumarol is administered as a racemic mixture of Rand S-enantiomers that differ in their potency and metabolism. S-acenocoumarol, which is a more potent vitamin K antagonist than the R-enantiomer is metabolized by the cytochrome P450 CYP2C9 (4) . To date, more than 50 CYP2C9 variants have been described. The CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) allele variants, especially the latter, are those that have more clinical consequences. Patients with the CYP2C9*3 variant require a lower dose of acenocoumarol than patients with the wild-type (wt) genotype, and are at higher risk for over-anticoagulation and serious bleeding (5, 6) . The enzyme vitamin K epoxide reductase (VKOR) encoded by the VKORC1 gene recycles vitamin K epoxide to the reduced form of vitamin K, an essential cofactor in the formation of the active clotting factors II, VII, IX, and X through γ-glutamyl carboxylation (7) . VKOR is the target of coumarin derivatives; several VKORC1 polymorphisms are associated with sensitivity to coumarin derivatives (7) (8) (9) (10) (11) (12) (13) (14) (15) . A single nucleotide polymorphism (SNP) in the gene promoter (VKORC1 c.-1639G>A) alters a transcription factor binding site, leading to reduced mRNA expression and subsequent total VKOR enzyme activity (7, 10) . This is reflected by a significant association between reduced acenocoumarol dose and the A allele of the aforementioned SNP in patients undergoing anticoagulant therapy (11) . The c.-1639G>A SNP (or alternatively the 1173C>T SNP) also explains around one third of the pharmacological response to acenocoumarol in non-patients (12) .
The association between patients' doses of warfarin (coumarin derivates used in the U.K. and U.S.) and each of CYP2C9*2 and *3 variants and VKORC1 c.-1639 G>A, 1173C>T and 3730G>A variants has been recently reported (8, 13, 14, 16, 17) , but whether this also applies to acenocoumarol remains to be corroborated. Particularly, the effects of CYP2C9 polymorphisms on the pharmacokinetics and anticoagulant response vary depending on the type of coumarin derivative being used as the CYP2C9 isoenzyme appears to be most important for the clearance of warfarin, followed by acenocoumarol and, lastly, phenprocoumon (3) .
The purpose of the present study was to assess the association of several variants alleles of CYP2C9 (*2 and *3) and VKORC1 (c.-1639G>A, 497C>G, 1173C>T and 3730G>A) with acenocoumarol dosage. In our study, acenocoumarol dosage was that required to achieve stable, effective anticoagulation in outpatients who had been anticoagulated for six or more months. We chose the aforementioned gene variants based on previous research showing their association with coumarin derivatives and on their high frequency among Caucasians (18) .
We selected 193 outpatients [100 men and 93 women; mean (SEM) age: 64 (1) years] meeting the following criteria: i) originally under treatment in the Hospital Clínico de San Carlos (Madrid, Spain) for one or more of the following conditions: atrial fibrillation, heart valve replacement with a metallic prosthesis, deep venous thrombosis, pulmonary thromboembolism or ischaemic stroke; ii) receiving oral anticoagulant therapy with acenocoumarol since the previous six or more months in the policlinic of the aforementioned Hospital under the supervision of an haematologist (with monthly international normalised ratio [INR] monitorization) for achieving stable coagulation, i.e. target INR of 3.0-4.0 in patients with a prosthetic heart valve and of 2.0-3.0 for the rest of patients; iii) having already met (at the time of enrolling the study) the aforementioned INR criteria; and iv) free of any concomitant severe disease known to interfere with acenocoumarol treatment (i.e. liver cirrhosis, uraemia and malignant diseases). For statistical analyses (see below), we reported their mean weekly dosage between January and May 2006. Table 1 : Genotypes of CYP2C9 and VKORC1 genes and acenocoumarol dose. A) Proportion and number of patients requiring low (<7 mg/ week), medium (7-28 mg/week) and high dose of acenocoumarol (> 28 mg/week) based on the different CYP2C9 and VKORC1 genotypes. Adjusted odds ratio (OR) for being at risk of needing a low (B) or medium dose (C) of acenocoumarol when carrying one or more allelic variants in CYP2C9 and VKORC1 genes. Analyses are adjusted for age and sex. CI, confidence interval.
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We extracted genomic DNA from peripheral EDTA-treated anti-coagulated blood according to standard phenol/chloroform procedures followed by alcohol precipitation. For CYP2C9 *2 and *3 and for VKORC1 3730G>A we used real-time polymerase chain reaction (PCR) followed by melting curve analysis with fluorescence resonance energy transfer probes with a thermal cycler (Light Cycler 2.0 IVD, Roche Diagnostics, Barcelona, Spain). For the VKORC1 polymorphisms c.-1639G>A, 497C>G, and 1173C>T we used a specific PCR followed by single base extension using capillary electrophoresis (ABI Prism 310 Applied Biosystems, Foster City, CA, USA). To ensure proper internal control, for each genotype analysis we used positive and negative controls from different DNA aliquots which were previously genotyped with the same method.
The procedures followed were in accordance with the ethical standards of our institutional committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Documented review and approval from the institutional Ethics committee (Universidad Europea de Madrid, Spain) was obtained, and all participants (see below) provided their written informed consent.
We evaluated the association between acenocoumarol dose requirements and the different CYP2C9 and VKORC1 variants with multivariable logistic regression after adjusting for age and gender. Further analyses were performed after additionally controlling for treatment (or not) with other drugs that can interfere with the anticoagulant effect of acenocoumarol, i.e. angiotensing converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, statins, beta-blockers, Ca 2+ antagonists, anti aggregants, digoxin, valproic acid, anticonvulsant drugs that are enzymatic inductors (phenytoin, carbamazepine and phenobarbital) and amiodarone. Each genetic variant was examined in a separate regression model. The level of significance was set at 0.05.
The number and proportion of patients by genotype is shown in Table 1A . The number of patients with atrial fibrillation needing low, medium and high dose was four, 26 and four, respectively. The number of patients with heart valve prostesis was 10 (low), 26 (medium), and five (high dose); with venous thrombosis zero (low), 14 (medium), and zero (high dose); with pulmonary thromboembolism zero (low), two (medium), and zero (high dose); and with ischaemic stroke six (low), three (medium), and one (high dose).
The risk of requiring a low dose of acenocoumarol was significantly increased (p<0.05) in patients carrying at least one CYP2C9*3 allele, the VKORC1 genotypes c.-1639 AA, 497 CG and GG, and 1173 TT, and at least one mutant 3730 A allele (Table 1B) . The adjusted odds ratio (OR) for being at risk of requiring a moderate dose of acenocoumarol when carrying an allelic variant are displayed Table 1C . Neither age nor gender affected the acenocoumarol requirement in any of the analyses. The results did not materially change after controlling for the above mentioned drugs that can interfere with the anticoagulant effect of acenocoumarol. Likewise, the results did not change after additionally controlling for CYP2C9 *2 and/or *3.
Collectively, these data confirm and extent previous pioneer findings (5, 6, 11-13, 19, 20) by showing that: i) patients with the CYP2C9 *3 (not with the *2) variant require a lower acenocoumarol dose than wt patients as the *3 allele independently and strongly predicts the required dose of this drug; and ii) all the commonest VKORC1 polymorphisms, included 3730G>A (the most frequent VKORC1 polymorphism in Caucasians [18] ) influence acenocoumarol dose, with the risk of requiring low doses significantly increasing in carriers of one or more mutant allele.
Our design is limited by the fact that we did not account for the potential confounding effect that variations in patients' weight and diet (particularly L-carnitine supplements or dietary content of fruits and vegetables) have on coumarin sensitivity. There were two main novelties in our report with regard to previous relevant research in the field. First, we assessed the association between all CYP2C9 and VKORC1 polymorphisms that are candidates to have an influence on anticoagulant dose requirements and the required dosage of acenocoumarol. Though the association between the c.-1639G>A (10, 11) and 1173C>T polymorphisms of VKORC1 and acenocoumarol dose has been extensively studied in recent years (12, 13, 19, 20) , a novel finding reported here was that the 1173C>T variant does also influence the dosage of this coumarin derivative. Second, we studied the pharmacogenetics of acenocoumarol in a relatively large number of patients anticoagulated for six months or more and achieving stable anticoagulation. Bodin et al. (12) assessed the influence of the polymorphisms studied here (expect the VKORC1 3730G>A) and acenocoumarol sensitivity in healthy individuals; recent relevant studies on European patients reported the association between CYP2C9 and VKORC1 genotypes and acenocoumarol during the initial phases of anticoagulant therapy (19, 20) or in bleeders (13) ; and in the previous reports on Spanish patients receiving acenocoumarol the influence of all the CYP2C9 and VKORC1 variants we studied here was not assessed (5, 6, 11) .
In summary, variations in CYP2C9 (*3) and VKORC1 (c.-1639G>A, 497C>G, 1173C>T and 3730G>A) genotypes explain individual variations in the dose required to achieve stable, effective acenocoumarol treatment in outpatients anticoagulated for six or more months, independently of age, gender or concomitant treatment with other drugs. Although research is necessary to determine the cost-benefit ratio of the proposed intervention, genetic screening on the studied genetic variants might be of clinical use in anticoagulated patients.
